ArticleOncology letters2016
High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Impact of Activation ofMedicina (Kaunas, Lithuania) · 2022Article
- Progress of EGFL6 in angiogenesis and tumor development.International journal of clinical and experimental pathology · 2022Review
- Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling.Cancers · 2020Review
- WGCNA reveals key gene modules regulated by the combined treatment of colon cancer with PHY906 and CPT11.Bioscience reports · 2020Article
- The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models.Blood advances · 2020Article
- The emerging role of EGFL6 in angiogenesis and tumor progression.International journal of medical sciences · 2020Review
- Novel Expression of EGFL7 in Osteosarcoma and Sensitivity to Cisplatin.Frontiers in oncology · 2020Article
- Endothelial Cell Activation Is Regulated by Epidermal Growth Factor-like Domain 7 (Egfl7) during Inflammation.The Journal of biological chemistry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor blood vessels participate in the immune response against cancer cells and we previously used pre-clinical models to demonstrate that egfl7 (VE-statin) promotes tumor cell evasion from the immune system by repressing endothelial cell activation, preventing immune cells from entering the tumor mass. In the present study, the expression levels of egfl7 and that of ICAM-1 as a marker of endothelium activation, were evaluated in peritumoral vessels of human breast cancer samples. Breast cancer samples (174 invasive and 30
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.